United States - English - NLM (National Library of Medicine)

dutch ophthalmic research center (international) b.v. - trypan blue (unii: i2zwo3ls3m) (trypan blue free acid - unii:768n7qo4kh) - trypan blue 0.75 mg in 0.5 ml - membraneblue™ 0.15% is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue. membraneblue™ 0.15% is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (iol) is planned to be inserted into the eye. the dye may be absorbed by the iol and stain it. teratogenic effects: pregnancy category c. trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. the majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. the teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. these doses are approximately 4,000- and 2,000-fold the maximum recommended human dose of 0.75 mg per injection based on a 60 kg person, assuming that the whole dose is completely absorved. characteristic anomalies included neural tube, cardiovascular,

United States - English - NLM (National Library of Medicine)

d.o.r.c. dutch ophthalmic research center (international) b.v. - trypan blue (unii: i2zwo3ls3m) (trypan blue free acid - unii:768n7qo4kh) - trypan blue 0.3 mg in 0.5 ml - visionblue® 0.06% is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens. visionblue® 0.06% is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (iol) is planned to be inserted into the eye. the dye may be absorbed by the iol and stain it. teratogenic effects: pregnancy category c. trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. the majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. the teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. these doses are approximately 10,000- and 5,000-fold the maximum recommended human dose of 0.3 mg per injection based in a 60 kg person, assuming that the whole dose is completely absorbed. characteristic anomalies included neural tube, cardiovascular, vertebral, tail, and eye defects. trypan blue also caused an increase in post-im

United States - English - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - urogesic-blue™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urogesic-blue™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urogesic-blue™ has not been reported and due to the nature of its ingredients, abuse of urogesic-blue™ is not expected.

United States - English - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - urogesic-blue™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urogesic-blue™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urogesic-blue™ has not been reported and due to the nature of its ingredients, abuse of urogesic-blue™ is not expected.

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - clopidogrel besilate - film-coated tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; clopidogrel

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - atorvastatin calcium trihydrate - film-coated tablet - 10 milligram(s) - atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - atorvastatin calcium trihydrate - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - atorvastatin calcium trihydrate - film-coated tablet - 30 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - atorvastatin calcium trihydrate - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - atorvastatin calcium trihydrate - film-coated tablet - 60 milligram(s) - hmg coa reductase inhibitors; atorvastatin